CA2391357C - A process for producing crystalline atorvastatin calcium - Google Patents
A process for producing crystalline atorvastatin calcium Download PDFInfo
- Publication number
- CA2391357C CA2391357C CA002391357A CA2391357A CA2391357C CA 2391357 C CA2391357 C CA 2391357C CA 002391357 A CA002391357 A CA 002391357A CA 2391357 A CA2391357 A CA 2391357A CA 2391357 C CA2391357 C CA 2391357C
- Authority
- CA
- Canada
- Prior art keywords
- methyl tert
- butyl ether
- atorvastatin
- product
- vessel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Abstract
A factory scale process for producing crystalline atorvastatin calcium includes the step of drying the isolated product in a vacuum pan dryer. The vacuum pan dryer has an agitator which is continuously rotated at a speed of approximately 1 rpm.
High quality material is routinely and consistently produced with reduced cycle time.
High quality material is routinely and consistently produced with reduced cycle time.
Description
A PROCESS FOR PRODUCING CRYSTALLINE ATORVASTATIN CALCIUM
Introduction The invention relates to an improved process for producing crystalline atorvastatin calcium which is known by the chemical name [R- (R*, R*)]-2- (4-fluorophenyl)- P, 6-dihydroxy-5-(1-rnethylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-IH- pyrrole-l-heptanoic acid hemi calcium salt.
Atorvastatin is useful as a selective and competitive inhibitor of the enzyme hydroxy-3-methylglutaryl-coenzyme A(IMG-CoA) reductase, the rate- limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols such as cholesterol. The conversion of HMG- CoA to mevalonate is an early and rate-limiting step in cholesterol biosynthesis.
Atorvastatin as well as some of its metabolites are pharmacologically active in humans and are thus useful as a hypolipidemic and hypocholesterolemic agent. The liver is the primary site of action and the principal site of cholesterol synthesis. Clinical and pathological studies show that elevated plasma levels of total cholesterol and associated triglycerides promote human atherosclerosis and are risk factors for developing cardiovascular disease.
United States Patent Number 4,681,893 discloses certain trans-6- [2- (3- or 4-carboxamido-substituted-pyrrol-1-yl) alkyl]-4-hydroxy-pyran-2-ones including trans ( )-5-(4-fluorophenyl)-2- ( 1 -methylethyl)-N,4-diphenyl- 1 - [
(2-tetrahydro-4-hydroxy-6-oxo-2H-pyran- 2-yl) ethyl]-1H-pyrrole-3-carboxamide.
United States Patent Number 5,273,995 discloses the enantiomer having the R
form of the ring-opened acid of trans-5- (4-fluorophenyl)-2- ( 1-methylethyl)-N, 4-diphenyl-l- [
Introduction The invention relates to an improved process for producing crystalline atorvastatin calcium which is known by the chemical name [R- (R*, R*)]-2- (4-fluorophenyl)- P, 6-dihydroxy-5-(1-rnethylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-IH- pyrrole-l-heptanoic acid hemi calcium salt.
Atorvastatin is useful as a selective and competitive inhibitor of the enzyme hydroxy-3-methylglutaryl-coenzyme A(IMG-CoA) reductase, the rate- limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols such as cholesterol. The conversion of HMG- CoA to mevalonate is an early and rate-limiting step in cholesterol biosynthesis.
Atorvastatin as well as some of its metabolites are pharmacologically active in humans and are thus useful as a hypolipidemic and hypocholesterolemic agent. The liver is the primary site of action and the principal site of cholesterol synthesis. Clinical and pathological studies show that elevated plasma levels of total cholesterol and associated triglycerides promote human atherosclerosis and are risk factors for developing cardiovascular disease.
United States Patent Number 4,681,893 discloses certain trans-6- [2- (3- or 4-carboxamido-substituted-pyrrol-1-yl) alkyl]-4-hydroxy-pyran-2-ones including trans ( )-5-(4-fluorophenyl)-2- ( 1 -methylethyl)-N,4-diphenyl- 1 - [
(2-tetrahydro-4-hydroxy-6-oxo-2H-pyran- 2-yl) ethyl]-1H-pyrrole-3-carboxamide.
United States Patent Number 5,273,995 discloses the enantiomer having the R
form of the ring-opened acid of trans-5- (4-fluorophenyl)-2- ( 1-methylethyl)-N, 4-diphenyl-l- [
(2-tetrahydro-4- hydroxy-6-oxo-2H-pyran-2-yl) ethyl]-1H-pyrrole-3-carboxamide, i. e., [R-(R*, R*)]-2-(4-fluorophenyl)-P,S-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-l-heptanoic acid.
The above described atorvastatin compounds have been prepared by a superior convergent route disclosed in the following United States Patent Numbers 5,003,080;
5,097,045;
5,103,024; 5,124,482 and 5,149,837 and Baumann K. L., Butler D. E., Deering C.
F., et al, Tetrahedron Letters 1992; 33: 2283-2284.
One of the critical intermediates disclosed in United States Patent Number 5,097,045 has also been produced using novel chemistry, as disclosed in United States Patent Number 5,155,251, which is herein incorporated by reference and Brower P. L., Butler D. E., Deering C. F., et al, Tetrahedron Letters 1992; 33: 2279- 2282.
United States Patent Numbers 5,216,174; 5,245,047; 5,248,793; 5,280.126;
5,397,792;
5,342,952; 5,298,627; 5,446,054; 5,470,981; 5,489,690; 5,489,691; 5,109,488;
5,969,156;
US6,087,511; US5,998,663 and W099/32434 disclose various processes and key intermediates for preparing atorvastatin.
It has been found that when the process for preparing atorvastatin calcium was scaled up to a commercial factory scale drying was slow and difficult to optimise.
It was also found that wet crystalline atorvastatin calcium was susceptible to possible break up with physical attrition and furthermore had a propensity to form rock hard clods on mixing.
The above described atorvastatin compounds have been prepared by a superior convergent route disclosed in the following United States Patent Numbers 5,003,080;
5,097,045;
5,103,024; 5,124,482 and 5,149,837 and Baumann K. L., Butler D. E., Deering C.
F., et al, Tetrahedron Letters 1992; 33: 2283-2284.
One of the critical intermediates disclosed in United States Patent Number 5,097,045 has also been produced using novel chemistry, as disclosed in United States Patent Number 5,155,251, which is herein incorporated by reference and Brower P. L., Butler D. E., Deering C. F., et al, Tetrahedron Letters 1992; 33: 2279- 2282.
United States Patent Numbers 5,216,174; 5,245,047; 5,248,793; 5,280.126;
5,397,792;
5,342,952; 5,298,627; 5,446,054; 5,470,981; 5,489,690; 5,489,691; 5,109,488;
5,969,156;
US6,087,511; US5,998,663 and W099/32434 disclose various processes and key intermediates for preparing atorvastatin.
It has been found that when the process for preparing atorvastatin calcium was scaled up to a commercial factory scale drying was slow and difficult to optimise.
It was also found that wet crystalline atorvastatin calcium was susceptible to possible break up with physical attrition and furthermore had a propensity to form rock hard clods on mixing.
The object of the present invention is therefore to provide a process for producing crystalline atorvastatin calcium on a factory scale which routinely and consistently produces high quality material with reduced cycle time.
Statements of Invention According to the invention there is provided a process for producing crystalline atorvastatin trihydrate hemi calcium salt comprising the steps of:-reacting a mixture of atorvastatin lactone, methanol and methyl tert-butyl ether with sodium hydroxide to form the ring-opened sodium salt;
forming a product rich aqueous layer and an organic layer comprising methyl tert-butyl ether containing impurities;
removing the organic layer comprising methyl tert-butyl ether containing impurities;
extracting the product rich aqueous layer with methyl tert-butyl ether;
adding an extra charge of methyl tert-butyl ether to a vessel containing the product rich aqueous layer in an amount of at least 1% w/v of the contents of the vessel;
sealing the reaction vessel;
heating the contents of the sealed reaction vessel to 47 to 57 C in the presence of the extra charge of methyl tert-butyl ether which saturates the crystallisation matrix on heating;
Statements of Invention According to the invention there is provided a process for producing crystalline atorvastatin trihydrate hemi calcium salt comprising the steps of:-reacting a mixture of atorvastatin lactone, methanol and methyl tert-butyl ether with sodium hydroxide to form the ring-opened sodium salt;
forming a product rich aqueous layer and an organic layer comprising methyl tert-butyl ether containing impurities;
removing the organic layer comprising methyl tert-butyl ether containing impurities;
extracting the product rich aqueous layer with methyl tert-butyl ether;
adding an extra charge of methyl tert-butyl ether to a vessel containing the product rich aqueous layer in an amount of at least 1% w/v of the contents of the vessel;
sealing the reaction vessel;
heating the contents of the sealed reaction vessel to 47 to 57 C in the presence of the extra charge of methyl tert-butyl ether which saturates the crystallisation matrix on heating;
adding calcium acetate hemihydrate to the sealed reaction vessel to form atorvastatin trihydrate hemi calcium salt; and drying the isolated product in a vacuum pan dryer having an agitator which is continuously rotated at a speed of from 0.5 to 2rpm.
It has been surprisingly found that this continuous agitation at a very low speed provides optimum drying conditions with very significant increased throughput while avoiding clod formation and particle attrition. As more solvents are evaporated from the cake in the dryer the crystals are increasingly susceptible to attrition. The process ensures that no break-up occurs with physical attrition.
Clod formation on mixing is also avoided.
In a particularly preferred embodiment of the invention the agitator is substantially continuously rotated at a speed of approximately 1rpm. This provides reduced drying time while ensuring uniform drying of the crystals and avoidance of clod formation and particle attrition. We have found that this uniform drying ensures that all water is evenly removed from the cake in the dryer.
In a preferred embodiment the vacuum in the pan dryer is maintained at from -0.80 to -0.99 bar.
Preferably the isolated product is dried over a period of from 1 to 4 days, ideally over a period of from 1 to 2 days.
Detailed description Atorvastatin lactone is saponified in a water/methyl alcohol/methyl tert-butyl ether (2-methoxy-2-methyl-propane; tert-butyl methyl ether) mixture with sodium hydroxide. The aqueous layer containing the sodium salt of atorvastatin is washed with methyl tert-butyl ether to remove small quantities of process impurities.
A
small aliquot of methyl tert-butyl ether is added to the crystallisation matrix.
Sodium-to-calcium salt metathesis with concurrent crystallisation is accomplished by the slow addition of an aqueous calcium acetate solution to the sodium salt solution. To ensure crystallisation simultaneous with addition, the reaction mixture is seeded with crystalline atorvastatin shortly after the start of the calcium acetate addition. The product is isolated by filtration and, after washing with water/methyl alcohol and water is centriftiged and vacuum dried before milling to give crystalline atorvastatin as the trihydrate. The reaction scheme is shown below.
F F
O
1. 2NaOH(aq)/ OH OH 0 2 _ ::: Ca+3H\ ~ - + 2Na0 rl't4 y y o O
Scheme 1 We have surprisingly found that the drying of atorvastatin calcium has a sensitive window of moisture content of approximately 6% w/v where the drying has to proceed slowly in order to prevent the particles from breaking down. As more solvents are evaporated from the cake in the dryer, especially around 6%
water, the particles are increasingly susceptible to attrition.
We have found that continuous agitation at approximately lrpm significantly reduces the drying time compared to an intermittent agitation technique, thereby increasing drying capacity while ensuring that the final dried product is within a consistent range for particle size and bulk density. This is in complete contrast to continuous medium speed agitation which results in clod formation and the risk of physical attrition and intermittent agitation which substantially increases the required drying time.
Continuous agitation at 0.5 to 2 rpm is outside the normal design operating range of agitated pan dryers.
Example 1 250kg atorvastatin lactone prepared as described in US 5,273,995, 1028kg methyl tert-butyl ether and 496kg of methanol are charged to a 6000 litre glass lined reaction vessel. The reaction mixture is agitated and heated to about 30 C to dissolve the lactone.
When the lactone is dissolved, approximately 3200 litres of caustic solution is added (19kg of sodium hydroxide 97.5% dissolved in 31651itres of deionised water). The contents of the vessel are heated to 47 to 57 C and agitated for at least 45 minutes.
After cooling to 25 to 35 C under an inert atmosphere the contents are allowed to settle and the organic layer is discarded. 765kg methyl tert-butyl ether is charged to the aqueous layer, the contents mixed and allowed to settle. The organic layer is discarded.
63kg of extra methyl tert-butyl ether is charged to the product rich aqueous layer in the reaction vessel which is then sealed. The contents of the sealed reaction vessel are heated to 47 to 57 C maintaining a pressurised system.
A solution of calcium acetate (40kg calcium acetate hemihydrate in 1365 litres deionised water) is transferred to the pressurised vessel. Shortly after commencement of the calcium acetate addition the transfer is stopped and atorvastatin trihydrate hemi calcium salt seed, prepared as described in US5,969,156, is introduced.
It has been surprisingly found that this continuous agitation at a very low speed provides optimum drying conditions with very significant increased throughput while avoiding clod formation and particle attrition. As more solvents are evaporated from the cake in the dryer the crystals are increasingly susceptible to attrition. The process ensures that no break-up occurs with physical attrition.
Clod formation on mixing is also avoided.
In a particularly preferred embodiment of the invention the agitator is substantially continuously rotated at a speed of approximately 1rpm. This provides reduced drying time while ensuring uniform drying of the crystals and avoidance of clod formation and particle attrition. We have found that this uniform drying ensures that all water is evenly removed from the cake in the dryer.
In a preferred embodiment the vacuum in the pan dryer is maintained at from -0.80 to -0.99 bar.
Preferably the isolated product is dried over a period of from 1 to 4 days, ideally over a period of from 1 to 2 days.
Detailed description Atorvastatin lactone is saponified in a water/methyl alcohol/methyl tert-butyl ether (2-methoxy-2-methyl-propane; tert-butyl methyl ether) mixture with sodium hydroxide. The aqueous layer containing the sodium salt of atorvastatin is washed with methyl tert-butyl ether to remove small quantities of process impurities.
A
small aliquot of methyl tert-butyl ether is added to the crystallisation matrix.
Sodium-to-calcium salt metathesis with concurrent crystallisation is accomplished by the slow addition of an aqueous calcium acetate solution to the sodium salt solution. To ensure crystallisation simultaneous with addition, the reaction mixture is seeded with crystalline atorvastatin shortly after the start of the calcium acetate addition. The product is isolated by filtration and, after washing with water/methyl alcohol and water is centriftiged and vacuum dried before milling to give crystalline atorvastatin as the trihydrate. The reaction scheme is shown below.
F F
O
1. 2NaOH(aq)/ OH OH 0 2 _ ::: Ca+3H\ ~ - + 2Na0 rl't4 y y o O
Scheme 1 We have surprisingly found that the drying of atorvastatin calcium has a sensitive window of moisture content of approximately 6% w/v where the drying has to proceed slowly in order to prevent the particles from breaking down. As more solvents are evaporated from the cake in the dryer, especially around 6%
water, the particles are increasingly susceptible to attrition.
We have found that continuous agitation at approximately lrpm significantly reduces the drying time compared to an intermittent agitation technique, thereby increasing drying capacity while ensuring that the final dried product is within a consistent range for particle size and bulk density. This is in complete contrast to continuous medium speed agitation which results in clod formation and the risk of physical attrition and intermittent agitation which substantially increases the required drying time.
Continuous agitation at 0.5 to 2 rpm is outside the normal design operating range of agitated pan dryers.
Example 1 250kg atorvastatin lactone prepared as described in US 5,273,995, 1028kg methyl tert-butyl ether and 496kg of methanol are charged to a 6000 litre glass lined reaction vessel. The reaction mixture is agitated and heated to about 30 C to dissolve the lactone.
When the lactone is dissolved, approximately 3200 litres of caustic solution is added (19kg of sodium hydroxide 97.5% dissolved in 31651itres of deionised water). The contents of the vessel are heated to 47 to 57 C and agitated for at least 45 minutes.
After cooling to 25 to 35 C under an inert atmosphere the contents are allowed to settle and the organic layer is discarded. 765kg methyl tert-butyl ether is charged to the aqueous layer, the contents mixed and allowed to settle. The organic layer is discarded.
63kg of extra methyl tert-butyl ether is charged to the product rich aqueous layer in the reaction vessel which is then sealed. The contents of the sealed reaction vessel are heated to 47 to 57 C maintaining a pressurised system.
A solution of calcium acetate (40kg calcium acetate hemihydrate in 1365 litres deionised water) is transferred to the pressurised vessel. Shortly after commencement of the calcium acetate addition the transfer is stopped and atorvastatin trihydrate hemi calcium salt seed, prepared as described in US5,969,156, is introduced.
A seed slurry is prepared by charging 37 litres deionised water and 13kg methanol to a stainless steel make-up/delivery vessel. The solvent mixture is agitated by rocking the vessel back and forth on its cradle. 3.6kg atorvastatin calcium seed crystals are then charged to the solvent mixture. The contents of the delivery vessel are mixed by rocking until a seed slurry is formed. Sufficient pressure is applied to the make-up/delivery vessel so that its pressure is higher than that of the reaction vessel. The make-up/delivery vessel is attached to the reaction vessel via a flexible hose and the seed slurry is charged rapidly over 2 to 3 minutes, under pressure, into the reaction vessel.
After the addition of the seed slurry the calcium acetate addition is immediately resumed to complete the calcium transfer.
The product cake is washed first with a methanol/water solution followed by a water wash.
Example 2: Drying of atorvastatin calcium The wet product prepared in Example 1 is loaded into a stainless steel continuous agitation pan dryer such as a Guedu Pan Dryer. A full vacuum of from -0.80 to -0.99 bar is applied, the jacket of the dryer adjusted to 60 to 70 C and the product dried with slow continuous agitation at approximately lrpm for at least 24 hours, preferably for from 1 to 4 days, ideally 1 to 2 days.
The dry product is then loaded into clean poly-lined drums.
The invention is not limited to the embodiments hereinbefore described which may be varied in detail.
After the addition of the seed slurry the calcium acetate addition is immediately resumed to complete the calcium transfer.
The product cake is washed first with a methanol/water solution followed by a water wash.
Example 2: Drying of atorvastatin calcium The wet product prepared in Example 1 is loaded into a stainless steel continuous agitation pan dryer such as a Guedu Pan Dryer. A full vacuum of from -0.80 to -0.99 bar is applied, the jacket of the dryer adjusted to 60 to 70 C and the product dried with slow continuous agitation at approximately lrpm for at least 24 hours, preferably for from 1 to 4 days, ideally 1 to 2 days.
The dry product is then loaded into clean poly-lined drums.
The invention is not limited to the embodiments hereinbefore described which may be varied in detail.
Claims (5)
1. A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt comprising the steps of:-reacting a mixture of atorvastatin lactone, methanol and methyl tert-butyl ether with sodium hydroxide to form the ring-opened sodium salt;
forming a product rich aqueous layer and an organic layer comprising methyl tert-butyl ether containing impurities;
removing the organic layer comprising methyl tert-butyl either containing impurities;
extracting the product rich aqueous layer with methyl tert-butyl ether;
adding an extra charge of methyl tert-butyl ether to a vessel containing the product rich aqueous layer in an amount of at least 1% w/v of the contents of the vessel;
sealing the reaction vessel;
heating the contents of the sealed reaction vessel to 47 to 57°C in the presence of the extra charge of methyl tert-butyl ether which saturates the cyrstallisation matrix on heating;
adding calcium acetate hemihydrate to the sealed reaction vessel to form atorvastatin trihydrate hemi calcium salt; and drying the isolated product in a vacuum pan dryer having an agitator which is continuously rotated at a speed of from 0.5 to 2rpm.
forming a product rich aqueous layer and an organic layer comprising methyl tert-butyl ether containing impurities;
removing the organic layer comprising methyl tert-butyl either containing impurities;
extracting the product rich aqueous layer with methyl tert-butyl ether;
adding an extra charge of methyl tert-butyl ether to a vessel containing the product rich aqueous layer in an amount of at least 1% w/v of the contents of the vessel;
sealing the reaction vessel;
heating the contents of the sealed reaction vessel to 47 to 57°C in the presence of the extra charge of methyl tert-butyl ether which saturates the cyrstallisation matrix on heating;
adding calcium acetate hemihydrate to the sealed reaction vessel to form atorvastatin trihydrate hemi calcium salt; and drying the isolated product in a vacuum pan dryer having an agitator which is continuously rotated at a speed of from 0.5 to 2rpm.
2. A process as claimed in claim 1 wherein the agitator is substantially continuously rotated at a speed of approximately 1rpm.
3. A process as claimed in claim 1 or 2 wherein the vacuum in the pan dryer is maintained at from-0. 80 to-0.99 bar.
4. A process as claimed in any one of claims 1-3 wherein the isolated product is dried over a period of from 1 to 4 days.
5. A process as claimed in any one of claims 1-4 wherein the isolated product is dried over a period of from 1 to 2 days.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE9900133 | 1999-12-17 | ||
| IEPCT/IE99/00133 | 1999-12-17 | ||
| PCT/IE2000/000151 WO2001044181A1 (en) | 1999-12-17 | 2000-12-18 | A process for producing crystalline atorvastatin calcium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2391357A1 CA2391357A1 (en) | 2001-06-21 |
| CA2391357C true CA2391357C (en) | 2009-01-06 |
Family
ID=11042529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002391357A Expired - Fee Related CA2391357C (en) | 1999-12-17 | 2000-12-18 | A process for producing crystalline atorvastatin calcium |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6605728B2 (en) |
| EP (1) | EP1242373B1 (en) |
| JP (1) | JP2003517039A (en) |
| AT (1) | ATE320415T1 (en) |
| AU (1) | AU780247B2 (en) |
| CA (1) | CA2391357C (en) |
| DE (1) | DE60026737T2 (en) |
| ES (1) | ES2258030T3 (en) |
| HU (1) | HUP0203798A3 (en) |
| IL (2) | IL149088A0 (en) |
| MX (1) | MXPA02004082A (en) |
| WO (1) | WO2001044181A1 (en) |
| ZA (1) | ZA200203649B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ294695B6 (en) | 1995-07-17 | 2005-02-16 | Warner-Lambert Company | Crystalline Form II atorvastatin or hydrate thereof, pharmaceutical composition in which said Form II atorvastatin is comprised and its use in medicine |
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| ATE420070T1 (en) | 2000-12-27 | 2009-01-15 | Teva Pharma | CRYSTALLINE FORMS OF ATORVASTATIN |
| CN1524073A (en) * | 2001-06-29 | 2004-08-25 | ����-�����ع�˾ | Crystalline forms of 'r-(r*,r*)-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| US7074818B2 (en) * | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
| US7563911B2 (en) * | 2001-08-31 | 2009-07-21 | Morepen Laboratories Ltd. | Process for the preparation of amorphous atorvastin calcium salt (2:1) |
| US20060020137A1 (en) * | 2001-11-29 | 2006-01-26 | Limor Tessler | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2003070702A1 (en) * | 2002-02-15 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
| EP1465901A4 (en) | 2002-02-19 | 2006-02-01 | Teva Pharma | Processes for desolvating solvates of atorvastatin hemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent |
| IL150907A (en) * | 2002-07-25 | 2007-07-04 | Stephan Cherkez | Process for the preparation of stable amorphous calcium pseudomonate |
| CA2508871C (en) * | 2002-11-28 | 2008-09-09 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| EP1424324A1 (en) * | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Crystalline form F of Atorvastatin hemi-calcium salt |
| MX2007000582A (en) * | 2004-07-16 | 2007-03-30 | Lek Pharmaceuticals | Oxidative degradation products of atorvastatin calcium. |
| WO2006048888A1 (en) * | 2004-11-01 | 2006-05-11 | Jubilant Organosys Limited | Novel process for the preparation of amorphous atorvastatin calcium salt |
| DE602005013007D1 (en) * | 2005-09-10 | 2009-04-09 | Ulkar Kimya Sanayii Ve Ticaret | PROCESS FOR THE PRODUCTION OF LACTONES |
| CN102249978A (en) * | 2011-06-09 | 2011-11-23 | 浙江金立源药业有限公司 | KY crystal form of Atorvastatin calcium and preparation method thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3288288A (en) * | 1963-06-28 | 1966-11-29 | Johns Manville | Art of filtration |
| US3852480A (en) * | 1972-04-11 | 1974-12-03 | Beatrice Foods Co | Bland soy protein |
| US3897307A (en) * | 1974-10-23 | 1975-07-29 | Hansens Lab Inc | Stabilized dry cultures of lactic acid-producing bacteria |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| NL8800801A (en) | 1988-03-30 | 1989-10-16 | Philips Nv | DATA PROCESSING SYSTEM WITH CYCLIC DATA BUFFERING, SELECTORS FOR SELECTING MEMORY ADDRESS, SUITABLE FOR USE IN SUCH A SYSTEM. |
| FI94339C (en) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
| US5102648A (en) * | 1990-03-02 | 1992-04-07 | Olin Corporation | Process for the production of lithium hypochloride |
| US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| CZ294695B6 (en) * | 1995-07-17 | 2005-02-16 | Warner-Lambert Company | Crystalline Form II atorvastatin or hydrate thereof, pharmaceutical composition in which said Form II atorvastatin is comprised and its use in medicine |
| US6087511A (en) | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| IL127058A (en) | 1996-07-29 | 2001-07-24 | Warner Lambert Co | Process for the synthesis of protected esters of (s)-3,4- dihydroxybutyric acid |
| ATE360608T1 (en) | 1997-12-19 | 2007-05-15 | Pfizer Ireland Pharmaceuticals | METHOD FOR PRODUCING 1,3-DIOLS |
-
2000
- 2000-12-18 MX MXPA02004082A patent/MXPA02004082A/en active IP Right Grant
- 2000-12-18 IL IL14908800A patent/IL149088A0/en active IP Right Grant
- 2000-12-18 HU HU0203798A patent/HUP0203798A3/en unknown
- 2000-12-18 CA CA002391357A patent/CA2391357C/en not_active Expired - Fee Related
- 2000-12-18 ES ES00985735T patent/ES2258030T3/en not_active Expired - Lifetime
- 2000-12-18 AT AT00985735T patent/ATE320415T1/en not_active IP Right Cessation
- 2000-12-18 AU AU22143/01A patent/AU780247B2/en not_active Ceased
- 2000-12-18 EP EP00985735A patent/EP1242373B1/en not_active Expired - Lifetime
- 2000-12-18 DE DE60026737T patent/DE60026737T2/en not_active Expired - Fee Related
- 2000-12-18 JP JP2001545269A patent/JP2003517039A/en active Pending
- 2000-12-18 WO PCT/IE2000/000151 patent/WO2001044181A1/en active IP Right Grant
-
2002
- 2002-04-11 IL IL149088A patent/IL149088A/en not_active IP Right Cessation
- 2002-05-08 ZA ZA200203649A patent/ZA200203649B/en unknown
- 2002-06-14 US US10/172,614 patent/US6605728B2/en not_active Expired - Fee Related
-
2003
- 2003-08-08 US US10/637,886 patent/US6730797B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0203798A2 (en) | 2003-03-28 |
| US6730797B2 (en) | 2004-05-04 |
| US6605728B2 (en) | 2003-08-12 |
| US20040024226A1 (en) | 2004-02-05 |
| ES2258030T3 (en) | 2006-08-16 |
| HUP0203798A3 (en) | 2008-10-28 |
| IL149088A0 (en) | 2002-11-10 |
| WO2001044181A1 (en) | 2001-06-21 |
| EP1242373B1 (en) | 2006-03-15 |
| AU780247B2 (en) | 2005-03-10 |
| MXPA02004082A (en) | 2002-10-11 |
| ZA200203649B (en) | 2002-12-20 |
| IL149088A (en) | 2007-03-08 |
| DE60026737D1 (en) | 2006-05-11 |
| AU2214301A (en) | 2001-06-25 |
| ATE320415T1 (en) | 2006-04-15 |
| US20020161239A1 (en) | 2002-10-31 |
| DE60026737T2 (en) | 2006-09-21 |
| JP2003517039A (en) | 2003-05-20 |
| EP1242373A1 (en) | 2002-09-25 |
| CA2391357A1 (en) | 2001-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2391357C (en) | A process for producing crystalline atorvastatin calcium | |
| AU776613B2 (en) | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt | |
| CZ12198A3 (en) | Crystalline semi-calcerous salt of /r-(r*r*)/-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-/(phenylamino)carbonyl/-1h- pyrrole-1-heptanoic acid (atorvastatin) | |
| WO2002083637A1 (en) | Process for the production of amorphous atorvastatin calcium | |
| EP1922315B1 (en) | Preparation of an atorvastatin intermediate | |
| IE20001032A1 (en) | An improved process for producing crystalline atorvastatin calcium | |
| IES20001033A2 (en) | An improved process for producing crystalline atorvastation calcium | |
| WO2005073187A1 (en) | Improved process for the preparation of amorphous atorvastatin calcium | |
| IE20001034A1 (en) | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt | |
| JP2009507822A (en) | Preparation of atorvastatin intermediate | |
| IES20001035A2 (en) | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt | |
| IE84049B1 (en) | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt | |
| US20050165242A1 (en) | Process for the preparation of amorphous atorvastatin calcium | |
| IE20050594A1 (en) | A process for preparing atorvastatin lactone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |